期刊文献+

环孢素A和他克莫司对肾移植受者血脂的影响 被引量:2

Effects of cyclosporine A and tacrolimus on blood lipid of renal transplant recipients
下载PDF
导出
摘要 背景:高血脂为肾移植后常见的并发症,常用的免疫抑制剂包括环孢素A,泼尼松和他克莫司都会对患者血脂产生影响。目的:探讨他克莫司与环孢素对肾移植术后患者血脂的影响。方法:按照不同的服药方案将肾移植后的患者随机分成2组:环孢素A组(n=20),免疫抑制剂方案为环孢素A+麦考酚酸莫酯+泼尼松;他克莫司组(n=23),免疫抑制剂方案为他克莫司+麦考酚酸莫酯+泼尼松。于移植前,移植后1个月及6个月对患者抽血化验,观察两组患者总胆固醇、三酰甘油、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇的变化。结果与结论:两组各项指标移植前后比较均有差异,两组间比较,移植后1个月和6个月总胆固醇和低密度脂蛋白胆固醇差异显著(P<0.05);高密度脂蛋白胆固醇和三酰甘油之间差异不显著。结果表明:对肾移植后肾功能稳定的患者实施以环孢素A为免疫抑制剂的方案,三酰甘油和低密度脂蛋白胆固醇更易升高,他克莫司在脂类代谢方面表现出更少的不良反应。与环孢素A相比,肾移植后患者应用他克莫司高脂血症的发病率明显降低。 BACKGROUND:Hyperlipidemia following successful renal transplantation is a frequent and persistent complication.Several immunosuppressive agents, including cyclosporine A (CsA), corticosteroids, and tacrolimus, appear to have a significant pathogenetic role.OBJECTIVE:To investigate the differential effects of tacrolimus and CsA on blood lipids in renal transplant recipients.METHODS:Renal transplant recipients treated with a different combination of immunosuppressive agents were divided into CsA(n=20) group, who received CsA+mycophenolatemofetil (MMF)+steroids and tacrolimus (n=23) group, who treated by tacrolimus+MMF+steroids.Plasma lipids, including total cholesterol, triglycerides, low-density lipoprotein cholesterol (C-LDL) andhigh-density lipoprotein cholesterol (C-HDL) were examined prior to, 1 and 6 months after transplantation.RESULTS AND CONCLUSION:There were statistically significant differences between the two groups prior to and after transplantation.Total cholesterol levels and C-LDL levels were significantly different when compared between the two groups at 1and 6 months after transplantation.The differences of C-HDL and triglycerides were not statistically significant.The results demonstrated that, triglycerides and C-LDL levels are prone to increase in renal transplant recipients received CsA therapy, and the hyperlipidemia is less pronounced in patients given tacrolimus.Compared with CsA, tacrolimus appears lower the attack rateof lipid metabolism.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2010年第44期8207-8210,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献6

二级参考文献64

  • 1王振,高江平,罗芸,卢锦山,敖建华,肖序仁,洪宝发,石炳毅,薛毅珑.不同浓度他克莫司在体外对胰岛的毒性作用及致糖尿病作用的临床研究[J].中华器官移植杂志,2006,27(11):681-684. 被引量:15
  • 2王振,石炳毅,高江平,罗芸.免疫抑制剂对人胰岛细胞的毒性作用[J].解放军医学杂志,2007,32(1):43-45. 被引量:3
  • 3Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation [ J ]. Transplantation, 2008, 85 ( 2 ):209-216.
  • 4Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacroiimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature [ J ]. Transpl Int, 2008, 21(2) :146-151.
  • 5Lentine KL, Brennan DC. Statin use after renal transplantation : a systematic quality review of trial-based evidence [ J ]. Nephrol Dial Transplant, 2004, 19 (9) :2378-2386.
  • 6Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant [J]. N Engl J Med, 1999, 341(23) :1725-1730.
  • 7Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients [ J ]. Am J Kidney Dis, 2007, 49 (2) :294-300.
  • 8Shimmura H, Tanabe K, Tokumoto T, et al. Analysis of cause of death with a functioning graft : a single-center experience [ J]. Transplant Proc, 2004, 36 (7) :2026-2029.
  • 9Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation [ J ]. Transplantation, 2008, 85 ( 2 ) : 209-216.
  • 10Jeloka TK, Ross H, Smith R, et al. Renal transplant outcome in high-cardiovascular risk recipients [ J]. Clin Transplant, 2007, 21 (5) :609-614.

共引文献34

同被引文献21

  • 1唐春华,刘炜,凌建煜.肾移植受者血清IL-10测定的临床意义[J].上海交通大学学报(医学版),2006,26(6):685-688. 被引量:1
  • 2Arce J,Rosales A,Caffaratti J,et al.Renal retransplantation: risk factors and results.Actas Urol Esp.2011: 35(1):44-50.
  • 3Steinmetz OM,Stahl RA,Panzer U.Chemokines and B cells in renal inflammation and allograft rejection.Front Biosci.2009: 1:13-22.
  • 4Badiou S, Cristol JP, Mourad G.Dyslipidemia following kidney transplantation: diagnosis and treatment.Curr Diab Rep.2009: 9(4):305-311.
  • 5Calmus Y, Pageaux G.Renal failure following liver transplantation Presse Med.2009: 38(9):1314-1318.
  • 6Marcen R.Immunosuppressive drugs in kidney transplantation: impact on patient survival,and incidence of cardiovascular disease,malignancy and infection.Drugs.2009:69(16):2227-2243.
  • 7Knoll G.Trends in kidney transplantation over the past decade. Drugs.2008; 68(Suppl 1):3-10.
  • 8Vicari-Christensen M,Repper S,Basile S,et aI.Tacrolimus: review of pharmacokinetics,pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence.Prog Transplant. 2009: 19(3):277-284.
  • 9Halloran PF.T cell-mediated rejection of kidney transplants: a personal viewpoint.Am J Transplant.2010; 10(5): 1126-1134.
  • 10Fischereder M, Schroppel B.The role of chemokines in acute renal allograft rejection and chronic allograft injury.Front Biosci. 2009: 14:1807-1814.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部